Sutro Biopharma (STRO) Receivables - Other (2017 - 2020)

Sutro Biopharma has disclosed Receivables - Other across 4 years of filings, most recently posting $6.4 million for Q1 2020.

• Receivables - Other for Q1 2020 came in at $6.4 million, up 439.06% year-over-year; the trailing twelve-month figure through Mar 2020 was $6.4 million (up 439.06% YoY), and the FY2019 annual result was $1.0 million, up 9.49% from the prior year.
• Receivables - Other came in at $6.4 million for Q1 2020 at Sutro Biopharma, up from $1.0 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $6.4 million in Q1 2020 to a low of $784000.0 in Q4 2017.
• The 4-year median for Receivables - Other is $1.1 million (2019), against an average of $1.9 million.
• Across the five-year window, Receivables - Other climbed 9.49% in 2019 and soared 439.06% in 2020, its largest moves.
• Sutro Biopharma's Receivables - Other stood at $784000.0 in 2017, then advanced by 22.32% to $959000.0 in 2018, then gained by 9.49% to $1.0 million in 2019, then soared by 509.9% to $6.4 million in 2020.
• The last three Receivables - Other figures came in at $6.4 million (Q1 2020), $1.0 million (Q4 2019), and $2.1 million (Q3 2019), per Business Quant data.